Results 71 to 80 of about 1,327 (120)

Continuation of Tarlatamab With Concomitant Radiotherapy for Oligoprogression in Extensive-Stage Small-Cell Lung Cancer: A Report of Two Cases. [PDF]

Cureus
Masui R, Omori S, Ueno T, Komiya K.
europepmc   +1 more source

Continuation of First-Line Systemic Therapy with Progression-Directed Radiotherapy in Patients with Oligoprogressive Hepatocellular Carcinoma: A Multicenter, Single-Arm, Phase II Trial. [PDF]

Clin Cancer Res
Shi F, Wang H, Yang Y, Ding L, Ding Y, Zhang Y, Xi M, Qu Y, Chen Z, Lu Y, Yang Y, Liu L, Yue J.   +12 more
europepmc   +1 more source

Oligoprogression During First-Line Treatment of Metastatic Hormone-Sensitive Prostate Cancer: Comparative Outcomes of Metastasis-Directed Radiotherapy and Systemic Treatment Change. [PDF]

J Clin Med
Günaltılı M, Guliyev M, Birsin Z, Çerme E, Aliyev V, Abbasov H, Cebeci S, Jeral S, Çiçek E, Atak S, Yıldırım HC, Demirci NS, Dinçbaş FÖ, Alan Ö.   +13 more
europepmc   +1 more source

Consensus statements on the definition, diagnosis, and management of oligoprogressive disease: results of an expert survey of Kazakhstan Cancer Society. [PDF]

Explor Target Antitumor Ther
Kaidarova D, Omarova I, Kaldarbekov S, Omarbayeva N, Dzhugashvili M, Ulrikh E, Alisheva D, Bereketov B, Tsimafeyeu I, Mitin T.   +9 more
europepmc   +1 more source

Progression-directed ablative radiotherapy improves event-free survival in oligoprogressive NSCLC. [PDF]

Front Oncol
De Sanctis L, Colciago RR, Rossano G, Ferrari M, Mombelli M, Manno I, Ferrario F, Saufi S, Faccenda V, Panizza D, Passarella G, Canova S, Cortinovis DL, Arcangeli S.   +13 more
europepmc   +1 more source

NED-oriented oncology in metastatic breast cancer: a hypothesis-driven framework integrating the tumor immune microenvironment, antibody-drug conjugates, and metastasis-directed therapy. [PDF]

Front Oncol
Kashiwagi S.
europepmc   +1 more source

Continuation of first-line therapy with progression-directed local therapy: a potential 1.5-line strategy bridging the gap between first- and second-line systemic therapy in oligoprogressive hepatocellular carcinoma. [PDF]

Hepatobiliary Surg Nutr
Zhang X, Yue J, Zhao L.
europepmc   +1 more source

Clinical outcomes and blood-based biomarkers across two SABR-treated metastatic settings: oligoprogression under immune checkpoint inhibition and oligometastatic disease. [PDF]

Oncoimmunology
Zafra-Martin J, Onieva JL, Jimenez-Rodriguez H, Martinez B, Figueroa-Ortiz L, Roman A, Ordoñez R, Pérez-Ruiz E, Mesas A, Jurado JM, Salas B, Salcedo E, Chicas-Sett R, Rueda-Dominguez A, Barragan I.   +14 more
europepmc   +1 more source

Case Report: Exceptional long-term survival in metastatic pancreatic ductal adenocarcinoma after repeated high-dose hypofractionated lesion-directed radiotherapy. [PDF]

Front Oncol
Ding M, Song Z, Di Y, Wang Y, Ren G.
europepmc   +1 more source

Salvage Metastasectomy After Adoptive Cell Transfer for Melanoma: Long-Term Updates. [PDF]

Ann Surg Oncol
Dinerman AJ, Gustafson AM, Hitscherich KJ, White DE, Krishna S, Schrump DS, Hoang CD, Hernandez JM, Gartner JJ, Robbins PF, Kwong ML, Goff SL, Yang JC, Rosenberg SA, Klemen ND.   +14 more
europepmc   +1 more source